Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
RMD Open|January 8, 2026
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studiesPeter C Taylor, Arthur Kavanaugh, Louis Bessette, et al.
RMD Open|July 14, 2024
Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritisSofia Ramiro, Cédric Lukas, Louis Bessette, et al.
Rheumatology and Therapy|September 19, 2025
Safety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian SettingRegan Arendse, Proton Rahman, Philip Baer, et al.
Rheumatology and Therapy|February 28, 2024
Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE StudyVinod Chandran, Louis Bessette, Carter Thorne, et al.
Rheumatology and Therapy|March 13, 2026
Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS StudiesXenofon Baraliakos, Louis Bessette, Kurt de Vlam, et al.
Cartilage|June 13, 2015
Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4-Year Long-Term Observation following a Randomized Clinical Trial Using Chondroitin SulfateJean-Pierre Raynauld, Johanne Martel-Pelletier, Marc Dorais, et al.
Rheumatology and Therapy|September 11, 2023
Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical PracticeStephanie G Werner, Xenofon Baraliakos, Sabine Reckert, et al.
The Journal of Rheumatology|April 17, 2012
Sex differences in pain scores and localization in inflammatory arthritis: a systematic review and metaanalysisCheryl Barnabe, Louis Bessette, Cathy Flanagan, et al.
Lancet (London, England)|June 18, 2018
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trialGerd R Burmester, Joel M Kremer, Filip Van den Bosch, et al.
Clinical Therapeutics|May 28, 2018
Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION StudyJohn K Marshall, Louis Bessette, Neil H Shear, et al.
Pageof 12